ASX:IMU Imugene (IMU) Stock Price, News & Analysis → 4x Better than Bitcoin (From Behind the Markets) (Ad) Free IMU Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume12.70 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield3.03%Price TargetN/A Stock AnalysisStock Analysis Get Imugene alerts: Email Address Ad Behind the MarketsThe Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.Get the full story here >>> About Imugene Stock (ASX:IMU)Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… IMU Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business UpdateMarch 15, 2024 | finance.yahoo.comU.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for EnsartinibMarch 28, 2024 | Behind the Markets (Ad)The AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.March 14, 2024 | finance.yahoo.comPendulum Therapeutics Introduces GLP-1 ProbioticMarch 13, 2024 | finance.yahoo.comUnityPoint in Des Moines releases renderings for mental health expansionMarch 13, 2024 | finance.yahoo.comNovartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune SystemMarch 12, 2024 | finance.yahoo.comapoQlar enters into Collaboration with Mayo Clinic to Advance Patient Care with Extended Reality TechnologyMarch 11, 2024 | finanznachrichten.deImugene Limited: Phase 1 onCARlytics solid tumour trial advances to combination arm treatmentMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 11, 2024 | au.investing.comFIVE at FIVE AU: Biggest fall on ASX in eight monthsMarch 11, 2024 | au.investing.comImugene advances to combination dosing with Phase 1 onCARlytics solid tumour trialMarch 10, 2024 | afr.comBarrenjoey, Canaccord raising for Lake Resources; 39.1pc discountFebruary 22, 2024 | finance.yahoo.comImugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology CatalystsFebruary 20, 2024 | msn.com4 things a doctor who's written best-selling books about aging does daily in the hope of living longerFebruary 15, 2024 | proactiveinvestors.comImugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trialFebruary 3, 2024 | msn.comBritish Punjabi doctor leads ground-breaking international trial of bowel cancer vaccineJanuary 23, 2024 | finance.yahoo.comMaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy ProgramsJanuary 19, 2024 | finance.yahoo.comImugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers SymposiumJanuary 18, 2024 | proactiveinvestors.comImugene achieves ‘complete response’ with mid dose cancer trialJanuary 16, 2024 | fool.com.auWhy is ASX 300 healthcare stock Imugene jumping 14% today?January 16, 2024 | msn.comASX Health Stocks: Imugene gains on positive early signs from Phase 1 trialDecember 28, 2023 | au.investing.comImugene well positioned to deliver 2024 milestonesDecember 20, 2023 | morningstar.comImugene Ltd IUGNFDecember 11, 2023 | au.investing.comImugene and NeoImmuneTech in alliance to advance cancer treatmentDecember 11, 2023 | finance.yahoo.comNeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatmentsDecember 7, 2023 | proactiveinvestors.com.auImugene to open new PD1-Vaxx Phase 2 bowel cancer clinical trial in UK and AustraliaDecember 6, 2023 | finance.yahoo.comImugene to commence new phase 2 PD1-Vaxx bowel cancer trialSee More Headlines Receive IMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imugene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2019Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:IMU CUSIPN/A CIKN/A Webwww.imugene.com Phone61 3 9824 5254FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.37% Return on Assets-26.15% Debt Debt-to-Equity Ratio3.33 Current Ratio5.73 Quick Ratio15.17 Sales & Book Value Annual Sales$15.03 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.75 Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares7,390,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta3.23 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Paul Edward-Alexander Hopper A.S.i.A (Age 68)B.A (UNSW), FAICD, Executive Chairman Comp: $316.1kMs. Leslie ChongCEO, MD & Executive DirectorMr. Michael Tonroe ACA (Age 58)B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD, CFO & Company Secretary Comp: $424.28kDr. Nicholas J. Ede B.Sc.(Hons.)Ph.D., Head of Corporate DevelopmentDr. Monil Shah M.B.A.Pharm.D., Chief Business OfficerDr. Bradley Glover Ph.D. (Age 55)Chief Operating Officer Ms. Ursula McCurrySenior Vice President of Clinical OperationsDr. John ByonSenior Vice President of Clinical DevelopmentDr. Joseph Paul Woodard Jr.M.D., Chief Medical OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersPaul HopperSold 1,381,422 sharesTotal: $20,721.33 ($0.02/share)Lesley RussellSold 1,000,000 sharesTotal: $120,000.00 ($0.12/share)Paul HopperSold 535,714 sharesTotal: $24,107.13 ($0.05/share)Jens EcksteinSold 238,095 sharesTotal: $19,999.98 ($0.08/share) IMU Stock Analysis - Frequently Asked Questions How were Imugene's earnings last quarter? Imugene Limited (ASX:IMU) announced its earnings results on Thursday, February, 28th. The company reported $0.00 EPS for the quarter. What other stocks do shareholders of Imugene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Imugene investors own include Leap Therapeutics (LPTX), LightPath Technologies (LPTH), Jaguar Health (JAGX), Groupon (GRPN), Greenland Minerals (GGG), Fortescue (FMG), Diffusion Pharmaceuticals (DFFN), Alumina (AWC) and Atossa Therapeutics (ATOS). This page (ASX:IMU) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imugene Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.